First Round of abstract submission : August 25, 2017 | Welcome Message

Theme : Latest Technologies and Innovations in Vaccinology

Organizing Committee Members

ABOUT CONFERENCE

 

Science Access invites all the participants from all over the world to attend “International Conference on Vaccines and Immunology" to be held during April 16-18, 2018 Tokyo, Japan. The conference covers with the theme: Latest Technologies & Innovations in Vaccinology.

This logical gathering on Immunization will convey a chance to share potential advantages and constraints of antibodies in avoiding and control of infectious diseases and non-infectious diseases consequently improving the quality and longevity of life. Explore the ideas on Nanotechnology and Advances in Vaccine Technology. This session also discourses about the Pediatric Vaccination, vaccines in veterinary, plants and for pregnancy, Cancer Vaccines, Bacterial and Viral Vaccines

Standard immunization currently averts an estimated two to three million deaths every year in all age group. Innovative technology solutions that help to ensure vaccine effectiveness, efficiency, safety, and storage are enabling immunization programs to save even more lives and the current conference focus on Cancer Immunology, Molecular Immunology, and Clinical Immunology. Without vaccines as well as safe vaccine distribution and delivery practices, deaths, particularly in children, would increase dramatically. The impact of vaccines goes far beyond saving lives and recovering the health of HIV-infected people and HepatitisVaccination is in every sense an investment, with wider benefits that accrue across a lifetime. Enhancing financial security and reducing risk, eradicating infection through vaccination may lead to increased investment and improved political and economic stability and healthy people in the world.

Vaccine Conference 2018 brings all the top researchers, innovators and experts in the field with an opportunity to interact and discuss the latest technologies and challenges in Vaccinology. There is nothing more powerful than when this elite community comes together to share ideas, research matters, and hope.

And also the organizing committee is confident that participants will benefit from the high-value scientific program and welcome all the researchers and experts to join us for these 3 days of stimulating discussions, knowledge sharing.

Vaccine Conference 2018 conference organized at Tokyo. It is a most populous city and business hub of the Japan. Tokyo is a center of international trading and tourism and as the leading conference and exhibition venue in this part of the world.

Market Analysis of Vaccines:

The global vaccine market is expected to reach $57,885.4 million by 2019 from $33,140.6 million in 2014, at a CAGR of 11.8% from 2014 to 2019.

Key players in the Vaccine market

Astellas Pharma Inc. (Japan)

CSL Limited (Australia)

Emergent Bio Solutions, Inc. (U.S.)

GlaxoSmithKline, plc. (U.K.)

Johnson & Johnson (U.S.)

MedImmune, LLC (U.S.)

Merck & Co. (U.S.)

Pfizer, Inc. (U.S.)

Sanofi Pasteur (France)

Serum Institute of India Pvt. Ltd. (India)

The report segments this market on the basis of type, technology, disease indication, and end user. Among various end users, the pediatrics segment is expected to account for the largest share of the market and is expected to grow at the highest CAGR from 2014 to 2019. Growth in vaccine segment can be attributed to the rising prevalence of diseases and the increasing number of initiatives taken by government organizations for vaccination programs.

Based on geography, the global vaccines market is segmented into North America, Europe, Asia, and Rest of the World (RoW). North America is expected to account for the huge share of the market during the forecast period. The growth of this market is driven by factors such as increasing government support for vaccine development, rising company investments for vaccine research, and high prevalence of diseases.

THE VALUE OF VACCINES

Up to very recently decisions about vaccine implementation were simple to make. When three of five children were dying before the age of 25, having succumbed to smallpox, polio, tetanus, diphtheria, or other infectious diseases, it did not take sophisticated health economics calculations to decide whether vaccines to save their lives should be used. Thanks to the success of vaccines and hygiene practices, today parents, doctors, and healthcare officials no longer have firsthand experience with these devastating diseases, and often they question whether vaccines are still necessary or whether they are cost-effective. The recent economic crisis has challenged health care budgets and a lack of leadership in most decision-making bodies has pressured decision makers to use health economics analysis to decide on vaccine implementation. Unfortunately, there are no appropriate tools to calculate vaccine values, and tools imported from other disciplines have been used, especially therapy, to calculate the cost-effectiveness of vaccines. These primitive analyses restrict the calculation to cost or quality-adjusted life-year (QALY) and do not consider the real value of vaccination. As a consequence, the calculated value of vaccines is probably one or more orders of magnitude lower than the effective benefits that vaccines provide to society. Consequently, these tools lead to inaccurate decisions because vaccines are prioritized purely on the basis of economic considerations without calculating the price we would assign to a human life. To overcome this dilemma, the Institute of Medicine has developed a new platform termed “Strategic Multi Attribute Ranking Tool for Vaccines”, or SMART Vaccines, that tries to capture many of the tangible and intangible attributes of vaccination and enhance decision making. Capturing the value of better health in itself is essential to make better decisions, considering that people are willing to trade off income, pleasure, and convenience for an increase in the quality of life expectancy. A further example of how to improve the calculation of vaccine value is provided by Bloom and co-workers in this issue of PNAS.

Societies of vaccines

List of Vaccines Companies

Vaccines companies in Asia

Vaccines companies in Europe

  • Activartis
  • Hookipa Biotech
  • S-TARget Therapeutics
  • Themis Bioscience
  • Valneva
  • GlaxoSmithKline 
  • DanDrit Biotechnology
  • Bavarian Nordic
  • APCure
  • Imaxio Lyon
  • Valneva
  • Abivax Montpellier
  • Valneva
  • Abivax Paris
  • Onxeo Paris, France
  • Vaxon Biotech 
  • VitamFero
  • Bavarian Nordic
  • Emergent Bio Solutions 
  • Immatics Biotechnologies

Vaccines companies in America

  • IGNITE Immunotherapy
  • Dynavax Technologies
  • Novartis Diagnostics 
  • Entest Biomedical
  • CardioVax  
  • ImmunoScience  
  • Juvaris Pleasanton
  • Tolerion
  • Bavarian Nordic
  • PaxVax
  • Adamis Pharmaceuticals
  • BioMedicure
  • Inovio Pharmaceuticals
  • MabVax Therapeutics
  • MediGene
  • Novartis
  • PaxVax
  • Pfenex
  • Polynoma
  • Vical
  • Immudicon
  • Galena Biopharma
  • Meissa Vaccines
  • Pfizer
  • Nanotherapeutics
  • TapImmune 
  • Aurora Biopharma

vaccines@sasummits.com  

vaccinesummit@sasummits.com

 

 

big-event
big-event

Target Audience

  • Researchers & Scientists related to Vaccine R&D
  • Medical Colleges Faculty, Students
  • Vaccinology/Immunology Associations and Societies
  • Training Institutes
  • Business Entrepreneurs
  • Manufacturing Medical Devices Companies
  • Policy and decision makers with disciplines in the field of vaccination and therapeutics
  • Vaccine stakeholders including academic researchers, public health clinicians, veterinarians.

Contact Us

Feel Free To Contact Us

Address   : 2737 Live Oak Street, Huntington Park, CA, 90255, USA
Phone No : +1 - 267-646-2200
Fax           : +1 - 267-646-2200
Email Id    : vaccines@sasummits.com


MAIL US AT

 

Authorization Policy: By registering for the conference you grant permission to SCIENCEACCESS to photograph, film or record and use your name, likeness, image, voice and comments and to publish, reproduce, exhibit, distribute, broadcast, edit and/or digitize the resulting images and materials in publications, advertising materials, or in any other form worldwide without compensation. Taking of photographs and/or video recording by participants/others during conference is prohibited without prior approval. Contact us for any queries. Privacy is Everyone's Concern!